Top-Rated StocksTop-RatedNASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $34.82 +0.14 (+0.40%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$60.00 +25.18 (+72.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vaxcyte Stock (NASDAQ:PCVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxcyte alerts:Sign Up Key Stats Today's Range$34.50▼$36.5250-Day Range$31.38▼$37.3752-Week Range$27.66▼$121.06Volume990,221 shsAverage Volume1.15 million shsMarket Capitalization$4.49 billionP/E RatioN/ADividend YieldN/APrice Target$136.50Consensus RatingBuy Company Overview Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Read More Vaxcyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScorePCVX MarketRank™: Vaxcyte scored higher than 41% of companies evaluated by MarketBeat, and ranked 690th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has received no research coverage in the past 90 days.Read more about Vaxcyte's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.21) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -8.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -8.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxcyte's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.26% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.26% of the float of Vaxcyte has been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Vaxcyte has recently increased by 2.70%, indicating that investor sentiment is decreasing. News and Social Media3.5 / 5News Sentiment1.32 News SentimentVaxcyte has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Vaxcyte this week, compared to 7 articles on an average week.Search InterestOnly 4 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows3 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Stock News HeadlinesVaxcyte, Inc. (NASDAQ:PCVX) Receives $136.50 Average PT from AnalystsJuly 30 at 3:11 AM | americanbankingnews.comMizuho Maintains an Overweight Rating on Vaxcyte (PCVX)July 16, 2025 | insidermonkey.comHow we consistently pulled in $500 weekly in the last 4 monthsThe average household spends almost $6,500 every month in expenses… I’m talking about things like healthcare, food, transportation… Clothing, electricity… Just the bare necessities. Meanwhile, the average monthly income in the United States is only $4,935 a month… If we’re being honest that’s a huge income gap many folks can’t fill right now… But that’s exactly why I’m on a mission… To show a small group of people today exactly how they could start targeting an extra $500 or more week after week($10k starting stake)… Step-by-step. Starting right now. | Jack Carter Trading (Ad)Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP MeetingJuly 2, 2025 | msn.comVaxcyte: Sentiment Is Pushing The Shares DownJune 10, 2025 | seekingalpha.comHere’s Why Vaxcyte (PCVX) Sold Off in Q1May 27, 2025 | msn.comVaxcyte Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.comVaxcyte appoints new independent directorMay 3, 2025 | uk.investing.comSee More Headlines PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $81.86 at the start of the year. Since then, PCVX shares have decreased by 57.5% and is now trading at $34.82. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by $0.02. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Top institutional shareholders of Vaxcyte include TD Asset Management Inc (0.42%), Aberdeen Group plc (0.33%), Harbor Capital Advisors Inc. (0.08%) and Banque Pictet & Cie SA (0.06%). Insiders that own company stock include Jeff Fairman, Jim Wassil, Grant Pickering, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Teri Loxam, Heath Lukatch and Halley E Gilbert. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/14/2025Today7/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Vaxcyte$136.50 High Price Target$163.00 Low Price Target$90.00 Potential Upside/Downside+292.0%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$463.93 million Net MarginsN/A Pretax MarginN/A Return on Equity-17.12% Return on Assets-16.26% Debt Debt-to-Equity RatioN/A Current Ratio17.70 Quick Ratio17.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$26.52 per share Price / Book1.31Miscellaneous Outstanding Shares129,000,000Free Float125,005,000Market Cap$4.49 billion OptionableOptionable Beta1.19 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:PCVX) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.